Background In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease
inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon–ribavirin …

Background Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor
of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) …

Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the …

Background Current treatments for chronic hepatitis B are suboptimal. In the search for
improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus …

Background In clinical trials, treatment with a combination of the nucleotide polymerase
inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates …

Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (…

Background Since the release of the first global hepatitis elimination targets in 2016, and until
the COVID-19 pandemic started in early 2020, many countries and territories were making …

BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and
potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir …

Liver diseases have become a major health threat across Europe, and the face of European
hepatology is changing due to the cure of viral hepatitis C and the control of chronic viral …

Background and Aim: Decisions on public health issues are dependent on reliable
epidemiological data. A comprehensive review of the literature was used to gather country‐specific …